The X-Linked Hypophosphatemia Market is expected to register a CAGR of 3% to reach USD 40,309.1 Thousand by 2027. X-linked hypophosphatemia (XLH) is an inherited disorder characterized by low levels of phosphate in the blood. Treatment of X-linked hypophosphatemia basically includes phosphate supplementation, corrective surgery, dental treatment, and growth hormone therapy. X-linked hypophosphatemia can weaken bones, causing long-term disability and […]
